Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Withdrawn 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 4Sarcoma 2Lymphoid 2CNS 2Plasma cell 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Neoplasm Metastasis 4

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × repotrectinib × Tumor-Agnostic × Clear all
NCT05004116 2026-03-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
77 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05828303 2025-04-01

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Turning Point Therapeutics, Inc.

Phase 1/2 Terminated
9 enrolled 17 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT05828277 2023-09-26

A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

Turning Point Therapeutics, Inc.

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡